Abstract
Since the 1980s there has been a drive toward personalized targeted therapy for cancer. “Targeted cancer therapy” originally focused on inhibiting essential tumor survival factors, primarily protein tyrosine kinases. The complexity and rapid mutability of tumors, however, enable them to develop resistance to tyrosine kinase inhibitors (TKIs), even when these are multitargeted or applied in combination. This has led to the development of targeted cancer immunotherapy, to enhance immune surveillance against the tumor. In this paper, we provide a personal view of the development of targeted therapy, from TKIs to targeted immunotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 11579-11586 |
| Number of pages | 8 |
| Journal | Proceedings of the National Academy of Sciences of the United States of America |
| Volume | 116 |
| Issue number | 24 |
| DOIs | |
| State | Published - 11 Jun 2019 |
Bibliographical note
Publisher Copyright:© 2019 National Academy of Sciences. All rights reserved.
Keywords
- Cancer
- Immunotherapy
- Targeted therapy
- Tyrosine kinase
- Tyrphostin
